Latest News

STAT Plus: Most AbbVie shareholders are unfazed that the CEO’s bonus is tied to high prices for Humira

A prominent U.S. lawmaker may be upset that AbbVie (ABBV) ties the bonus given chief executive Richard Gonzalez to sales of the Humira rheumatoid arthritis treatment, but most shareholders seem unconcerned.

At the drug maker’s annual meeting on Friday, an overwhelming majority of stockholders rejected a proposal that would have required AbbVie to compile an annual report on how pricing is used to set executive compensation, according to a coalition of faith-based investor groups that submitted the proposal. On a preliminary basis, 69% of shareholders voted down the proposal.

Continue to STAT Plus to read the full story…

Source link

Related posts

Retired Justice Sandra Day O'Connor Has Dementia


US to force hospitals to reveal rates


25-year study shows that incidence of type 1 diabetes is increasing by more than 3 percent per year in Europe


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy